Citizens Jmp Reiterates “Market Perform” Rating for Cellectis (NASDAQ:CLLS)

Cellectis (NASDAQ:CLLS)‘s stock had its “market perform” rating reissued by investment analysts at Citizens Jmp in a note issued to investors on Tuesday, Benzinga reports.

Several other research firms have also recently issued reports on CLLS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellectis in a research report on Friday, July 17th. Barclays began coverage on shares of Cellectis in a research report on Thursday, May 28th. They set an “overweight” rating and a $9.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $7.00.

Cellectis Stock Performance

NASDAQ CLLS opened at $1.83 on Tuesday. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 1.61. The business’s 50 day moving average is $3.00 and its two-hundred day moving average is $3.34. Cellectis has a 12-month low of $1.75 and a 12-month high of $5.48. The stock has a market capitalization of $183.62 million, a price-to-earnings ratio of -2.82 and a beta of 2.92.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.04. Cellectis had a negative return on equity of 94.19% and a negative net margin of 102.34%.The business had revenue of $6.90 million during the quarter, compared to analysts’ expectations of $11.05 million.

Institutional Investors Weigh In On Cellectis

A hedge fund recently bought a new position in Cellectis stock. Lido Advisors LLC purchased a new position in Cellectis S.A. (NASDAQ:CLLS) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 10,094 shares of the biotechnology company’s stock, valued at approximately $32,000. Institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA (NASDAQ: CLLS) is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic T-cell therapies for cancer. The company uses its gene-editing technologies, including TALEN-based technology, to modify immune cells so they can be manufactured in advance and potentially administered to multiple patients rather than produced individually.

Cellectis’ product candidates are designed primarily as chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and other serious diseases.